Anastrozole, an aromatase inhibitor, has been added in the therapeutic regimen of four male patients with cabergoline-resistant prolactinomas and prolactin levels decreased (in one case it normalized) while the tumor size decreased by approximately 47% (mean reduction) without serious adverse events60. Here, PRL is linked to neoplasm.